- Home
- GIGM vs AEON Comparison
GIGM vs AEON Comparison
Compare GIGM & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | AEON |
|---|---|---|
| Founded | 1998 | N/A |
| Country | Taiwan | United States |
| Employees | N/A | 8 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 19.0M |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | GIGM | AEON |
|---|---|---|
| Price | $1.33 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 5.1K | ★ 876.7K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $0.24 |
| 52 Week High | $1.89 | $1.45 |
Technical Indicators
Market Signals| Indicator | GIGM | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 16.28 |
| Support Level | $1.30 | N/A |
| Resistance Level | $1.51 | $1.12 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 8.70 | 3.61 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.